These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 9563738)

  • 1. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E; Cohn J; Dubé L; Drazen JM
    JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
    Dekhuijzen PN; Bootsma GP; Wielders PL; van den Berg LR; Festen J; van Herwaarden CL
    Eur Respir J; 1997 Dec; 10(12):2749-53. PubMed ID: 9493655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
    Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A
    Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
    O'Connor BJ; Löfdahl CG; Balter M; Szczeklik A; Boulet LP; Cairns CB
    Respir Med; 2007 Jun; 101(6):1088-96. PubMed ID: 17360171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
    Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
    Fischer AR; McFadden CA; Frantz R; Awni WM; Cohn J; Drazen JM; Israel E
    Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1203-7. PubMed ID: 7551371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
    Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Rubin P; Cohn J; White MV; Igarashi Y; Kaliner MA; Drazen JM
    J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):1046-56. PubMed ID: 7798537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
    DuBuske LM; Grossman J; Dubé LM; Swanson LJ; Lancaster JF
    Am J Manag Care; 1997 Apr; 3(4):633-40. PubMed ID: 10169531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma.
    Yoshida S; Sakamoto H; Ishizaki Y; Onuma K; Shoji T; Nakagawa H; Hasegawa H; Nakabayashi M; Amayasu H
    Clin Exp Allergy; 2000 Jan; 30(1):64-70. PubMed ID: 10606932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
    Wenzel SE; Trudeau JB; Kaminsky DA; Cohn J; Martin RJ; Westcott JY
    Am J Respir Crit Care Med; 1995 Sep; 152(3):897-905. PubMed ID: 7663802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
    Nelson H; Kemp J; Berger W; Corren J; Casale T; Dube L; Walton-Bowen K; LaVallee N; Stepanians M
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):178-84. PubMed ID: 17718106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
    Diamant Z; Timmers MC; van der Veen H; Friedman BS; De Smet M; Depré M; Hilliard D; Bel EH; Sterk PJ
    J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):42-51. PubMed ID: 7822663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics.
    Micheletto C; Tognella S; Visconti M; Trevisan F; Dal Negro RW
    Respir Med; 2006 Dec; 100(12):2144-50. PubMed ID: 16678396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.
    Dahlén B; Kumlin M; Margolskee DJ; Larsson C; Blomqvist H; Williams VC; Zetterström O; Dahlén SE
    Eur Respir J; 1993 Jul; 6(7):1018-26. PubMed ID: 8396534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.
    Van Schoor J; Joos GF; Kips JC; Drajesk JF; Carpentier PJ; Pauwels RA
    Am J Respir Crit Care Med; 1997 Mar; 155(3):875-80. PubMed ID: 9117020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.
    Abraham WM; Ahmed A; Cortes A; Sielczak MW; Hinz W; Bouska J; Lanni C; Bell RL
    Eur J Pharmacol; 1992 Jul; 217(2-3):119-26. PubMed ID: 1330588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.